Randomized Placebo-controlled Trial of Sodium Valproate in Progressive Supranuclear Palsy

Highlights • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical neurology and neurosurgery 2016-07, Vol.146 (6), p.35-39
Hauptverfasser:	Leclair-Visonneau, Laurène, Rouaud, Tiphaine, Debilly, Bérangère, Durif, Franck, Houeto, Jean-Luc, Kreisler, Alexandre, Defebvre, Luc, Lamy, Estelle, Volteau, Christelle, Nguyen, Jean-Michel, Dily, Séverine Le, Damier, Philippe, Boutoleau-Bretonnière, Claire, Lejeune, Pascal, Derkinderen, Pascal
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alzheimer's disease Clinical medicine Cognitive science Cognitive Sciences Controlled-trial Dementia Double-Blind Method Electrolytes Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - pharmacology Family medical history Female Humans Inventory Kinases Life Sciences Male Middle Aged Neurobiology Neurology Neurons and Cognition Neuroprotection Neuroscience Neurosurgery Progressive supranuclear palsy Psychology and behavior Sodium Sodium valproate Studies Supranuclear Palsy, Progressive - drug therapy Syphilis Treatment Failure Valproic Acid - administration & dosage Valproic Acid - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP.
ISSN:	0303-8467 1872-6968
DOI:	10.1016/j.clineuro.2016.04.021